Dutch See First European Launch Of Clinuvel's Scenesse For Phototoxicity In EPP

Clinuvel is beginning the commercial launch in Europe of its orphan drug Scenesse for patients with erythropoietic protoporphyria, a rare condition that causes severe anaphylactic reactions and burns when the skin is exposed to sunlight.

Blue sky

Australian firm Clinuvel Pharmaceuticals Ltd. has announced the first commercial launch in Europe of its orphan drug Scenesse (afamelanotide) for the rare genetic disorder erythropoietic protoporphyria (EPP).

Patients in the Netherlands are this week beginning treatment with Scenesse, which received EU approval in 2014 for the prevention...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category